Long-Acting Toxins: What We Know

The promise of a botulinum toxin that "lasts longer" is seductive for patients and clinics alike: fewer office visits, lower reinjection costs, less time with movement returning. Whenever a manufacturer announces something in this direction, questions arise in the office. This page gathers a line of reasoning for handling the topic, without naming products or specific study figures.

The focus is critical reading. The decision on which product to use belongs to the qualified professional, in line with the rules of their professional council and the registration in force at ANVISA (Brazil's health regulatory agency).

What does "long-acting" mean for a toxin?

The term usually refers to two different things:

1. A modified formulation or molecule so that the clinical effect lasts longer compared with a reference product.
2. A strategy of use (technique, dose, interval) that, in theory, lengthens the period of effect, which is not a property of the product.

When people speak of a "long-acting toxin," the first meaning is the more common. But the definition of duration is complex: it can be the time until the patient notices movement returning, the time until the score on a scale goes back to baseline, or the time until a new injection is perceived as needed. Each outcome gives a different number.

For the basic concepts, see botulinum toxin: fundamentals, toxin latency and differences among type A botulinum toxins.

Why is duration hard to compare?

Even with established products, duration varies by individual and technical factors. This complicates any claim of superiority:

• Muscle treated: larger, more active muscles tend to respond differently from small muscles.
• Amount and distribution: the same molecule can last differently depending on the strategy.
• Metabolism and habits: intense physical activity, stress and habitual contraction can influence perception.
• Outcome chosen: duration of maximum effect, of minimum clinically relevant effect or of satisfaction.
• Assessment method: photo, observer-rated scale, patient self-assessment.

In comparisons between products there is also the problem of dose equivalence, which is not trivial and can be a source of bias. The page on levels of evidence in HOF helps organize this reading.

What to ask before adopting a new product?

An objective list of questions helps separate fact from marketing. Most can be answered by checking the registration and the package insert, and others by reading the published studies:

This check does not depend on any specific brand. It works for any novelty that appears, and protects the professional from adopting a product out of enthusiasm.

What can and cannot be said to the patient?

The patient wants a simple answer: "does it last longer or not?" The honest answer is that some products were developed with that proposal, that the available data may be early, and that clinical experience depends on each case. Avoid comparisons with other brands, out of respect for ethical rules, and make no promises about duration.

Is longer duration always an advantage?

Not always. In procedures with a narrow margin for adjustment, a toxin that lasts longer prolongs any unwanted effect. If a patient ends up with asymmetry, ptosis or a heavy look, those conditions last longer. Also, patients with a hyperactive muscle may need more frequent touch-ups, and prolonged duration may not translate into longer intervals.

There is also the patient's perspective: some value being able to "adjust" the result each cycle, which a longer effect makes harder. For people trying toxin for the first time, predictability and natural reversibility can be advantages.

Which patient profiles tend to ask about this?

The question comes from different motivations, and recognizing the motivation helps in answering. Patients with a tight schedule and little availability for return visits ask about convenience. Patients who have used toxin before and felt that it "wore off quickly" ask about performance. Patients who saw an ad or a social media profile ask out of curiosity and comparison. Some also associate a higher price with a better result and want "the strongest."

In each case, the conversation changes. For those short on time, it is worth showing that duration usually depends on the muscle and on habit, and that a predictable reinjection plan may serve better than switching products. For those who felt it wore off quickly, it is worth investigating: did the movement really return, or was it the perception that the skin remained marked by static lines? Often the complaint about short duration is really a complaint about indication or expectation. For the reasoning on failure and insufficient response, see botulinum toxin treatment failure.

As for price, never suggest that a higher price corresponds to a better or longer-lasting result. The cost-benefit decision is the patient's, and your role is to inform clearly what is known and what is not.

How to handle the topic in communication and advertising?

Advertising of new products is subject to the rules of your council and of CONAR (Brazil's advertising self-regulation council), and the practical rule is not to advertise duration, not to compare with other products and not to use language of superiority. Even in educational content, avoid duration figures without context and avoid attributing to the product qualities that the package insert does not state. If the patient arrives with an ad in hand, explain calmly that an ad does not replace an assessment.

Within the team, align the message: reception staff and assistants should not promise duration or compare products. Everyone should refer the question to the professional. See what can be advertised and front-desk training in HOF.

What about immunogenicity?

The discussion about repeated exposure and the formation of neutralizing antibodies connects with the topic: if a toxin lasts longer, in theory the patient is exposed fewer times. But that connection is a hypothesis, and the risk depends on many factors. See complexing proteins and antigenicity and reinjection and resistance risk for context.

How to stay up to date on the topic?

In a fast-changing field, it is worth building a follow-up routine. A few tips: follow the field's scientific societies, periodically check ANVISA information, read congress abstracts with skepticism and talk with trusted colleagues. See how to follow the scientific literature and scientific societies in HOF.

Practical summary

In practical terms, the professional can adopt a simple stance: use registered products, read the package insert and the literature, do not promise duration, explain individual variation and record the product and lot used. Novelty deserves a place only if it comes with data and safety. For the patient, what matters is that the indication is well made and follow-up is consistent.